PYXS241220P2500
- 0.59
- -0.11-15.71%
Pyxis Oncology Newsroom
A Quick Look at Today's Ratings for Pyxis Oncology(PYXS.US), With a Forecast Between $7 to $10
Pyxis Oncology Is Maintained at Outperform by RBC Capital
H.C. Wainwright Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $7
RBC Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Raises Target Price to $10
Pyxis Oncology Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Pyxis Oncology Analyst Ratings
RBC Boosts Price Target on Pyxis Oncology to $10 From $7, Keeps Outperform, Speculative Risk
William Blair Initiates Pyxis Oncology(PYXS.US) With Hold Rating
Stifel Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $10
RBC Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $7
H.C. Wainwright Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $7
LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating
Pyxis Oncology Initiated at Overweight by Stephens & Co.
Stephens Initiates Pyxis Oncology(PYXS.US) With Buy Rating, Announces Target Price $13
LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating
Leerink Partners Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Announces Target Price $12
Leerink Partners Maintains Pyxis Oncology(PYXS.US) With Buy Rating
RBC Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $7
Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS), Spruce Biosciences (SPRB) and Envista Holdings (NVST)
Pyxis Oncology Analyst Ratings